Your browser doesn't support javascript.
loading
Chromatin 3D interaction analysis of the STARD10 locus unveils FCHSD2 as a regulator of insulin secretion.
Hu, Ming; Cebola, Inês; Carrat, Gaelle; Jiang, Shuying; Nawaz, Sameena; Khamis, Amna; Canouil, Mickaël; Froguel, Philippe; Schulte, Anke; Solimena, Michele; Ibberson, Mark; Marchetti, Piero; Cardenas-Diaz, Fabian L; Gadue, Paul J; Hastoy, Benoit; Almeida-Souza, Leonardo; McMahon, Harvey; Rutter, Guy A.
Affiliation
  • Hu M; Section of Cell Biology and Functional Genomics, Department of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
  • Cebola I; Section of Genetics and Genomics, Department of Metabolism, Digestion, and Reproduction, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
  • Carrat G; Section of Cell Biology and Functional Genomics, Department of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
  • Jiang S; Section of Cell Biology and Functional Genomics, Department of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
  • Nawaz S; Oxford Centre for Diabetes Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Headington, Oxford OX3 7LE, UK.
  • Khamis A; Université de Lille, CNRS, CHU Lille, Institut Pasteur de Lille, UMR 8199 - EGID, 59000 Lille, France.
  • Canouil M; Université de Lille, CNRS, CHU Lille, Institut Pasteur de Lille, UMR 8199 - EGID, 59000 Lille, France.
  • Froguel P; Université de Lille, CNRS, CHU Lille, Institut Pasteur de Lille, UMR 8199 - EGID, 59000 Lille, France.
  • Schulte A; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany.
  • Solimena M; Paul Langerhans Institute of the Helmholtz Center Munich at the University Hospital and Faculty of Medicine, TU Dresden, 01307 Dresden, Germany.
  • Ibberson M; Vital-IT Group, SIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland.
  • Marchetti P; Department of Endocrinology and Metabolism, University of Pisa, 56126 Pisa, Italy.
  • Cardenas-Diaz FL; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA; Centre for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Gadue PJ; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA; Centre for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Hastoy B; Oxford Centre for Diabetes Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Headington, Oxford OX3 7LE, UK.
  • Almeida-Souza L; HiLIFE Institute of Biotechnology & Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland.
  • McMahon H; MRC MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK.
  • Rutter GA; Section of Cell Biology and Functional Genomics, Department of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK; Lee Kong Chian School of Medicine, Nan Yang Technological University, Singapore, Singapore. Electronic address: g.rutter@imperial.ac.uk.
Cell Rep ; 34(5): 108703, 2021 02 02.
Article in En | MEDLINE | ID: mdl-33535042
ABSTRACT
Using chromatin conformation capture, we show that an enhancer cluster in the STARD10 type 2 diabetes (T2D) locus forms a defined 3-dimensional (3D) chromatin domain. A 4.1-kb region within this locus, carrying 5 T2D-associated variants, physically interacts with CTCF-binding regions and with an enhancer possessing strong transcriptional activity. Analysis of human islet 3D chromatin interaction maps identifies the FCHSD2 gene as an additional target of the enhancer cluster. CRISPR-Cas9-mediated deletion of the variant region, or of the associated enhancer, from human pancreas-derived EndoC-ßH1 cells impairs glucose-stimulated insulin secretion. Expression of both STARD10 and FCHSD2 is reduced in cells harboring CRISPR deletions, and lower expression of STARD10 and FCHSD2 is associated, the latter nominally, with the possession of risk variant alleles in human islets. Finally, CRISPR-Cas9-mediated loss of STARD10 or FCHSD2, but not ARAP1, impairs regulated insulin secretion. Thus, multiple genes at the STARD10 locus influence ß cell function.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Phosphoproteins / Chromatin / Carrier Proteins / Insulin-Secreting Cells / Membrane Proteins Limits: Humans Language: En Year: 2021 Type: Article

Full text: 1 Database: MEDLINE Main subject: Phosphoproteins / Chromatin / Carrier Proteins / Insulin-Secreting Cells / Membrane Proteins Limits: Humans Language: En Year: 2021 Type: Article